Palvella Therapeutics, Inc. (PVLA)

Palvella Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	70.43	83.6	7.35	16.05
Cash & Short-Term Investments	70.43	83.6	7.35	16.05
Cash Growth	384.51%	1037.44%	-54.21%	-
Accounts Receivable	-	0.36	-	-
Other Receivables	1.98	1.98	-	-
Receivables	1.98	2.34	-	-
Prepaid Expenses	1.34	2.3	0.2	0.47
Total Current Assets	73.75	88.23	7.55	16.52
Total Assets	73.75	88.23	7.55	16.52
Accounts Payable	4.56	4.59	0.94	3.18
Accrued Expenses	2.16	4.29	1.26	2.44
Other Current Liabilities	2.9	3.17	0.17	0.16
Total Current Liabilities	9.62	12.04	2.36	5.78
Long-Term Debt	14.51	11.94	8.05	32.42
Other Long-Term Liabilities	1.84	1.65	1.01	1.5
Total Liabilities	25.97	25.63	11.43	39.7
Common Stock	0.01	0.01	-	-
Additional Paid-In Capital	159.27	156.33	1.82	1.22
Retained Earnings	-111.39	-93.74	-76.3	-94.99
Comprehensive Income & Other	-0.11	0	-	-
Total Common Equity	47.78	62.61	-74.48	-93.78
Shareholders' Equity	47.78	62.61	-3.88	-23.17
Total Liabilities & Equity	73.75	88.23	7.55	16.52
Total Debt	14.51	11.94	8.05	32.42
Net Cash (Debt)	55.92	71.66	-0.7	-16.36
Net Cash Per Share	8.15	32.19	-0.39	-2.86
Filing Date Shares Outstanding	11.06	11.02	5.72	5.72
Total Common Shares Outstanding	11.06	11.01	5.72	5.72
Working Capital	64.13	76.2	5.19	10.74
Book Value Per Share	4.32	5.69	-13.02	-16.40
Tangible Book Value	47.78	62.61	-74.48	-93.78
Tangible Book Value Per Share	4.32	5.69	-13.02	-16.40

Updated Aug 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q